Inhibition of IL-8 and stopping of immune cell infiltration using small molecules, either already available like dapsone or yet to be developed, should open a therapeutic window into the treatment of blistering diseases like EBS-DM. The gene discussed is CXCL8; the disease is epidermolysis bullosa simplex.